Medivir AB – Initiating as an Outperform - Next in HCV- A Once Daily Protease Inhibitor Option
We initiate our coverage on Medivir AB (MVIR) with an Outperform rating, as TMC435 (Protease Inhibitor, PhII/III, partnered with Tibotec/JNJ) could offer compelling advantages over recently launched PIs Incivek (Vertex/JNJ) and Victrelis (Merck). MVIR has a diversified Portfolio consists of both marketed and mature programs targeting viral diseases. TMC435 offers Dosing Advantage, once/daily pill vs. Incivek 2pills/3d and Merck’s Victrelis 4pills/3d besides…. For more detail, please read our report released on 24th June, 2011 on MVIR titled “Next in HCV- A Once Daily Protease Inhibitor Option”.
COMPANIES MENTIONED
Medivir AB, MVIR
Medivir AB, MVIR
